Suchen
Alnylam Pharmaceuticals Inc
ALNYZur Watchlist hinzufügen
293.520USD
+2.150+0.74%
Handelsschluss 06/29, 16:00（ET）Kurse um 15 Minuten verzögert
39.17BMarktkapitalisierung
71.84KGV TTM
mehr Informationen über Alnylam Pharmaceuticals Inc Unternehmen
Alnylam Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy in adults; ONPATTRO (patisiran) for the treatment of the polyneuropathy of hATTR amyloidosis in adults; GIVLAARI (givosiran) for the treatment of adults with acute hepatic porphyria; OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1, and Leqvio (inclisiran), which is being developed and commercialized by its partner, Novartis AG, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. The Company’s clinical development programs include Cemdisiran, Fitusiran, Zilebesiran, Elebsiran, Mivelsiran and ALN-HTT02. It is developing Cemdisiran to treat complement-mediated diseases.
Alnylam Pharmaceuticals Inc Informationen
BörsenkürzelALNY
Name des UnternehmensAlnylam Pharmaceuticals Inc
IPO-datumMay 28, 2004
CEOGreenstreet (Yvonne L)
Anzahl der mitarbeiter2230
WertpapierartOrdinary Share
GeschäftsjahresendeMay 28
Addresse675 W Kendall St
StadtCAMBRIDGE
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl02142-1168
Telefon16175518200
Websitehttps://www.alnylam.com/
BörsenkürzelALNY
IPO-datumMay 28, 2004
CEOGreenstreet (Yvonne L)
Führungskräfte von Alnylam Pharmaceuticals Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Yvonne L. Greenstreet, M.D.
Dr. Yvonne L. Greenstreet, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
56.38K
+7.29%
Mr. Jeffrey V. (Jeff) Poulton
Mr. Jeffrey V. (Jeff) Poulton
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
39.68K
+0.24%
Mr. Tolga Tanguler
Mr. Tolga Tanguler
Chief Commercial Officer
Chief Commercial Officer
15.33K
+5.62%
Dr. Dennis A. Ausiello, M.D.
Dr. Dennis A. Ausiello, M.D.
Independent Director
Independent Director
4.31K
+15.58%
Dr. Margaret A. Hamburg, M.D.
Dr. Margaret A. Hamburg, M.D.
Independent Director
Independent Director
807.00
+83.15%
Dr. Olivier Brandicourt, M.D.
Dr. Olivier Brandicourt, M.D.
Independent Director
Independent Director
671.00
--
Mr. Peter N. Kellogg
Mr. Peter N. Kellogg
Independent Director
Independent Director
671.00
--
Mr. David E. I. Pyott, CBE
Mr. David E. I. Pyott, CBE
Independent Director
Independent Director
--
--
Ms. Amy W. Schulman, J.D.
Ms. Amy W. Schulman, J.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Pushkal P. Garg, M.D.
Dr. Pushkal P. Garg, M.D.
Executive Vice President, Chief Research and Development Officer
Executive Vice President, Chief Research and Development Officer
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Yvonne L. Greenstreet, M.D.
Dr. Yvonne L. Greenstreet, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
56.38K
+7.29%
Mr. Jeffrey V. (Jeff) Poulton
Mr. Jeffrey V. (Jeff) Poulton
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
39.68K
+0.24%
Mr. Tolga Tanguler
Mr. Tolga Tanguler
Chief Commercial Officer
Chief Commercial Officer
15.33K
+5.62%
Dr. Dennis A. Ausiello, M.D.
Dr. Dennis A. Ausiello, M.D.
Independent Director
Independent Director
4.31K
+15.58%
Dr. Margaret A. Hamburg, M.D.
Dr. Margaret A. Hamburg, M.D.
Independent Director
Independent Director
807.00
+83.15%
Dr. Olivier Brandicourt, M.D.
Dr. Olivier Brandicourt, M.D.
Independent Director
Independent Director
671.00
--
Häufig gestellte Fragen
Wer sind die fünf größten Anteilseigner von Alnylam Pharmaceuticals Inc?
Die fünf größten Anteilseigner von Alnylam Pharmaceuticals Inc sind: Dr. Yvonne L. Greenstreet, M.D.
Wie viele Institutionen halten Anteile an Alnylam Pharmaceuticals Inc (ALNY)?
Mit Stand vom 2026Q1 halten 1634 Institutionen Anteile an Alnylam Pharmaceuticals Inc, mit einem Gesamtmarktwert von etwa 133.66M, was 100.11% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um -6052832.00 gestiegen.
Was ist die größte Einnahmequelle von Alnylam Pharmaceuticals Inc?
Am 2026Q1 erzielte das Geschäft mit AMVUTTRA für Alnylam Pharmaceuticals Inc den höchsten Umsatz in Höhe von 2.31B, was 62.30% des Gesamtumsatzes entspricht.
